Ingrezza Sprinkle Capsule
Product Images NDC 70370-4080

23 FDA label images from Neurocrine Biosciences, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Ingrezza Sprinkle (NDC 70370-4080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Neurocrine Biosciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ingrezza Contains Valbenazine, A Vesicular Monoamine Transporter 2 (vmat2) Inhibitor, Present As Valbenazine Tosylate Salt, With The Chemical Name, L-valine, (2r,3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-yl Ester, 4-methylbenzenesulfonate (1:2). Valbenazine Tosylate Is Slightly Soluble In Water. Its Molecular Formula Is C38h54n2o10s2, And Its Molecular Weight Is 762.97 G/mol (ditosylate Salt) With The Following Structure: (Valbenazine 01)

Ingrezza Contains Valbenazine, A Vesicular Monoamine Transporter 2 (vmat2) Inhibitor, Present As Valbenazine Tosylate Salt, With The Chemical Name, L-valine, (2r,3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-yl Ester, 4-methylbenzenesulfonate (1:2).  Valbenazine Tosylate Is Slightly Soluble In Water.  Its Molecular Formula Is C38h54n2o10s2, And Its Molecular Weight Is 762.97 G/mol (ditosylate Salt) With The Following Structure: (Valbenazine 01)
Chemical structure of valbenazine, the active ingredient in INGREZZA. The diagram shows the molecular framework with labeled carbon positions and sulfate counterions (2TsOH).*
FDA Label Image

Figure 1 (Valbenazine 02)

Figure 1 (Valbenazine 02)
This is a fold change and 90% confidence interval plot showing the impact of hepatic and renal impairment on the pharmacokinetics of Valbenazine and its metabolite [+]-α-HTBZ. The graph displays fold changes in Cmax and AUCinf comparing mild, moderate, and severe hepatic impairment and severe renal impairment relative to reference subjects.*
FDA Label Image

Figure 2 (Valbenazine 03)

Figure 2 (Valbenazine 03)
A chart illustrating fold change and 90% confidence intervals for valbenazine and its metabolite (+)-alpha-HTBZ under the influence of strong CYP2D6 inhibitor Paroxetine, strong CYP3A4 inducer Rifampin, and strong CYP3A4 inhibitor Ketoconazole. The x-axis represents change relative to reference (without interacting drug), ranging from 0.25 to 2.*
FDA Label Image

Figure 3 (Valbenazine 04)

Figure 3 (Valbenazine 04)
A horizontal line plot illustrating fold change and 90% confidence intervals for the pharmacokinetics of two substrates: CYP3A4 substrate Midazolam and P-gp substrate Digoxin. The x-axis shows change relative to reference from 0.5 to 4, while the y-axis lists Cmax and AUCinf parameters for each substrate, with data points and error bars reflecting the confidence intervals of these changes.*
FDA Label Image

Figure 4 (Valbenazine 05)

Figure 4 (Valbenazine 05)
A bar chart depicting the magnitude of improvement from baseline in AIMS Dyskinesia Total Score across patient groups treated with placebo, INGREZZA 40 mg, and INGREZZA 80 mg. The X-axis categorizes improvement levels from Missing to 10 to 13, while the Y-axis shows the percent of patients for each category. The chart compares percentages for placebo (white bars), INGREZZA 40 mg (gray bars), and INGREZZA 80 mg (black bars) groups, illustrating differences in patient outcomes.*
FDA Label Image

Figure 5 (Valbenazine 06)

Figure 5 (Valbenazine 06)
A line graph depicting change from baseline in AIMS Dyskinesia Total Score over time in weeks for various treatment groups: Placebo, INGREZZA 40 mg, INGREZZA 80 mg, and respective placebo-INGREZZA crossover groups. The x-axis shows time points from 0 to 52 weeks, divided into DB Phase, INGREZZA Extension Period, and Off Drug phases. The y-axis shows the change in score, ranging from 0 to -6. Patient numbers for each group are listed below the graph for corresponding time points.*
FDA Label Image

Figure6 (Valbenazine 07)

Figure6 (Valbenazine 07)
Label for INGREZZA 40 mg capsules containing valbenazine, with 30 capsules per package. The label includes storage instructions, a barcode, and distributor information for Neurocrine Biosciences, Inc., San Diego, CA. It is marked Rx only and states to keep out of reach of children.*
FDA Label Image

Figure7 (Valbenazine 08)

Figure7 (Valbenazine 08)
INGREZZA 60 mg capsules label showing a 30-capsule bottle. The label displays the proprietary name INGREZZA and generic name valbenazine, with dosage strength of 60 mg. The label includes storage instructions and distributor information for Neurocrine Biosciences, Inc., San Diego, CA.*
FDA Label Image

Figure A (Valbenazine 09)

Figure A (Valbenazine 09)
INGREZZA 80 mg capsules label showing a 30-capsule carton with active ingredient valbenazine indicated. The label includes storage instructions, distributor information for Neurocrine Biosciences, Inc., and a warning to keep out of reach of children. The dosage form is oral capsules.*
FDA Label Image

Figure B (Valbenazine 0a)

Figure B (Valbenazine 0a)
INGREZZA (valbenazine) capsules 40 mg and 80 mg oral capsules packaging label for a 4-week (28-day) initiation pack. The label displays dosage guidance for Week 1 (40 mg capsule daily) and Weeks 2-4 (80 mg capsule daily). The box includes instructions for opening and closing and is labeled by Neurocrine Biosciences, Inc. The label also includes the NDC code 70370-2048-6 and website information www.ingrezza.com.*
FDA Label Image

Figure C (Valbenazine 0b)

Figure C (Valbenazine 0b)
An instructional illustration showing a tablespoon being poured into a bowl, with an arrow indicating the direction from the spoon to the bowl. The image demonstrates a measurement or pouring action.*
FDA Label Image

Figure D (Valbenazine 0c)

Figure D (Valbenazine 0c)
An instructional illustration showing two hands holding and opening a capsule above a round container or bowl. The image likely demonstrates how to open or prepare the capsule for administration.*
FDA Label Image

Figure E (Valbenazine 0d)

Figure E (Valbenazine 0d)
An instructional illustration showing two hands pulling apart a capsule to empty its contents into a bowl below. This demonstrates how to open an oral capsule, likely related to the administration of the drug INGREZZA (valbenazine) capsules.*
FDA Label Image

Figure F (Valbenazine 0e)

Figure F (Valbenazine 0e)
An instructional illustration showing a hand stirring with a spoon in a bowl. The word 'Stir' with an arrow indicates the stirring motion, demonstrating a preparation or mixing step.*
FDA Label Image

Figure G (Valbenazine 0f)

Figure G (Valbenazine 0f)
Instructional illustration showing a hand discarding two capsules into a trash bin, likely representing proper disposal of INGREZZA capsules or medication waste.*
FDA Label Image

Ndc 70370-2040-1ingrezza(valbenazine) Capsules40 mg30 Capsulesrx Only (Valbenazine 10)

Ndc 70370-2040-1ingrezza(valbenazine) Capsules40 mg30 Capsulesrx Only (Valbenazine 10)
Label for INGREZZA 40 mg capsules containing valbenazine, an oral prescription drug by Neurocrine Biosciences, Inc. The label indicates a package size of 30 capsules, with storage instructions, child-resistant packaging, and a note that a Medication Guide is required. The label includes a barcode, lot, and expiration details.*
FDA Label Image

Ndc 70370-1060-1ingrezza(valbenazine) Capsules60 mg30 Capsulesrx Only (Valbenazine 11)

Ndc 70370-1060-1ingrezza(valbenazine) Capsules60 mg30 Capsulesrx Only (Valbenazine 11)
INGREZZA 60 mg capsules label showing a package of 30 capsules by Neurocrine Biosciences, Inc. The front panel includes the proprietary name INGREZZA with the generic name valbenazine, strength 60 mg, and orange highlight. It states Rx only and provides medication guide instructions and storage conditions.*
FDA Label Image

Ndc 70370-1080-1ingrezza(valbenazine) Capsules80 mg30 Capsulesrx Only (Valbenazine 12)

Ndc 70370-1080-1ingrezza(valbenazine) Capsules80 mg30 Capsulesrx Only (Valbenazine 12)
INGREZZA 80 mg capsules packaging label showing the brand name and generic name valbenazine. The label includes a quantity of 30 capsules, NDC 70370-1080-1, and emphasizes that medication guide is required. The labeler is Neurocrine Biosciences, Inc., with distribution address in San Diego, CA. Storage instructions and prescription drug status (Rx only) are also visible.*
FDA Label Image

Ndc 70370-2048-6ingrezza(valbenazine) Capsules7 X 40 mg / 21 X 80 mg Capsules28-day Initiation Packrx Only (Valbenazine 13)

Ndc 70370-2048-6ingrezza(valbenazine) Capsules7 X 40 mg / 21 X 80 mg Capsules28-day Initiation Packrx Only (Valbenazine 13)
INGREZZA (valbenazine) capsules, a 4-week (28-day) initiation pack for tardive dyskinesia, containing 7 capsules of 40 mg and 21 capsules of 80 mg, totaling 28 capsules. The package includes dosage instructions for Week 1 (one 40 mg capsule daily) and Weeks 2-4 (one 80 mg capsule daily). The labeler is Neurocrine Biosciences, Inc., and detailed opening and closing instructions for the pack sleeve are also depicted.*
FDA Label Image

Ndc 70370-2046-1ingrezza(valbenazine) Capsules14 X 40 mg / 14 X 60 mg Capsules28-day Initiation Packrx Only (Valbenazine 14)

Ndc 70370-2046-1ingrezza(valbenazine) Capsules14 X 40 mg / 14 X 60 mg Capsules28-day Initiation Packrx Only (Valbenazine 14)
INGREZZA (valbenazine) capsules 4-week initiation pack carton for oral capsules by Neurocrine Biosciences. It includes 40 mg capsules for weeks 1-2 and 60 mg capsules for weeks 3-4, totaling 28 capsules. The package features dosing instructions and a child-resistant closure mechanism with press, pull, fold, and push steps.*
FDA Label Image

Ndc 70370-4040-1ingrezza Sprinkle(valbenazine) Capsules40 mg30 Capsulesrx Only (Valbenazine 15)

Ndc 70370-4040-1ingrezza Sprinkle(valbenazine) Capsules40 mg30 Capsulesrx Only (Valbenazine 15)
Label for INGREZZA Sprinkle 40 mg capsules by Neurocrine Biosciences, Inc. The label indicates the product contains valbenazine and includes packaging information for 30 capsules. Storage instructions, dosage directions, child-resistant packaging notice, and a barcode are also visible. The label highlights prescription-only status and medication guide requirements.*
FDA Label Image

Ndc 70370-4060-1ingrezza Sprinkle(valbenazine) Capsules60 mg30 Capsulesrx Only (Valbenazine 16)

Ndc 70370-4060-1ingrezza Sprinkle(valbenazine) Capsules60 mg30 Capsulesrx Only (Valbenazine 16)
Label for INGREZZA SPRINKLE capsules containing 60 mg valbenazine, manufactured by Neurocrine Biosciences, Inc. The package contains 30 capsules and is identified for prescription use. The label includes storage instructions, dosage form as capsules for oral administration, a barcode, and child-resistant packaging information.*
FDA Label Image

Ndc 70370-4080-1ingrezza Sprinkle(valbenazine) Capsules80 mg30 Capsulesrx Only (Valbenazine 17)

Ndc 70370-4080-1ingrezza Sprinkle(valbenazine) Capsules80 mg30 Capsulesrx Only (Valbenazine 17)
Label for INGREZZA SPRINKLE (valbenazine) capsules, 80 mg strength, in a bottle of 30 capsules. The label includes storage instructions, dosage guidance to see prescribing information, and warnings to keep out of reach of children and not to eat desiccant. Distributed by Neurocrine Biosciences, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.